ASCO 2021
ASCO21: Gilead sets up first FDA okay for CAR-T in adult ALL with Tecartus data
Phil Taylor
acute lymphoblastic leukaemia, ASCO 2021, CAR-T therapies, Gilead Sciences, Kite Pharma, Kymriah, Novartis, Oncology, Tecartus
0 Comment
X
ASCO21: Gilead sets up first FDA okay for CAR-T in adult ALL with Tecartus data
https://pharmaphorum.com/news/asco21-gilead-sets-up-first-fda-okay-for-adult-all-with-tecartus-data/
ASCO21: Lynparza aces adjuvant breast cancer therapy trial
Phil Taylor
adjuvant, ASCO 2021, AstraZeneca, breast cancer, Lynparza, Merck & Co, Oncology, PARP inhibitor
0 Comment
X
ASCO21: Lynparza aces adjuvant breast cancer therapy trial
https://pharmaphorum.com/news/asco21-lynparza-aces-adjuvant-breast-cancer-therapy-trial/
ASCO21: Novartis’ prostate cancer radiotherapy extends survival
Phil Taylor
177Lu-PSMA-617, ASCO 2021, Novartis, Oncology, Prostate cancer, Radiopharmaceutical
0 Comment
X
ASCO21: Novartis’ prostate cancer radiotherapy extends survival
https://pharmaphorum.com/news/asco21-novartis-prostate-cancer-radiotherapy-extends-survival/